Last reviewed: June 4, 2026

Last updated: June 4, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Blood clot concerns have surfaced in discussions around Ozempic and other GLP-1 receptor agonists, creating confusion for patients considering weight loss treatment. Clinical trial evidence, however, shows no increased blood clot risk linked to semaglutide use in approved doses. Understanding the actual science behind these worries helps you make informed decisions about compounded GLP-1 therapy from PlexusDx.

Does Ozempic Actually Increase Blood Clot Risk?

Large randomized controlled trials of semaglutide, the active ingredient in Ozempic, have not documented elevated rates of deep vein thrombosis or pulmonary embolism in treated patients. The SUSTAIN trial series, which followed thousands of participants over multiple years, found no significant difference in thrombotic events between semaglutide and placebo groups. Regulatory agencies including the FDA have reviewed extensive safety data and found no warning language necessary regarding blood clots for standard-dose semaglutide therapy.

Confusion may arise because rapid weight loss itself—regardless of method—can theoretically increase clot risk in rare cases, particularly in patients with pre-existing clotting disorders or immobility. This relationship is not specific to GLP-1 medications but rather a general physiological response to significant body composition changes. PlexusDx screens patients for personal and family history of blood clotting conditions during initial intake to identify anyone requiring extra monitoring or specialist consultation.

How Semaglutide Affects Your Cardiovascular System

Semaglutide actually delivers cardiovascular benefits in addition to weight loss. The LEADER and SUSTAIN-6 trials demonstrated that semaglutide reduces the risk of major adverse cardiac events, including heart attack and stroke, particularly in patients with existing type 2 diabetes or cardiovascular disease. Weight reduction, improved blood sugar control, and lower blood pressure all contribute to better heart health outcomes in GLP-1 users.

PlexusDx compounded semaglutide works through the same GLP-1 receptor mechanism as Ozempic, offering identical pharmacological benefits without the brand-name markup. By starting at a lower dose and titrating upward based on your individual tolerance and response, personalized therapy minimizes side effects while maximizing metabolic benefits. Your dose may need to go up. Your price won't—PlexusDx keeps monthly costs flat across all dose levels.

Why Some Patients Fear Blood Clots With Weight Loss Drugs

Internet discussions and social media sometimes conflate unrelated side effects or misunderstand the connection between rapid weight loss and blood clot formation. Additionally, some older weight loss medications with banned substances did carry thrombotic risks, creating lasting skepticism toward newer therapies. Distinguishing between historical problems and current evidence-based medicine helps patients separate fact from misinformation.

Patients with specific genetic predispositions to clotting disorders should know their risk profile before starting any medication. PlexusDx's Precision Peptide Genetic Test identifies how your genes influence peptide metabolism and treatment response, though the test is not a clotting-disorder screening tool—that requires separate medical evaluation with your physician. This genetic insight ensures your personalized semaglutide protocol aligns with your metabolic and health characteristics.

What You Should Tell Your Doctor Before Starting Semaglutide

Disclose any personal history of blood clots, pulmonary embolism, deep vein thrombosis, or thrombophilia (inherited clotting disorder) to your PlexusDx provider and primary care physician. Mention family history of clotting conditions as well, since some genetic forms of hypercoagulability run in families. If you are immobilized for extended periods, recovering from recent surgery, or on anticoagulant medications, ensure your treatment team coordinates care appropriately.

PlexusDx sources all compounded semaglutide from licensed 503A compounding pharmacies, maintaining pharmaceutical standards equivalent to brand medications. Your personalized dosing schedule takes into account your unique medical history, current medications, and metabolic markers. Monthly costs start at $149 with no membership fee, and HSA and FSA accounts cover compounded semaglutide expenses—making safe, personalized therapy accessible without insurance barriers.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is Ozempic safe for people worried about blood clots?

Yes. Large clinical trials found no increased blood clot rates with semaglutide compared to placebo. If you have a personal or family history of clotting disorders, discuss this with your PlexusDx provider so your treatment plan accounts for your individual risk factors.

Can rapid weight loss from GLP-1 drugs cause blood clots?

Rapid weight loss itself carries theoretical thrombotic risk only in specific populations—those with pre-existing clotting disorders or prolonged immobility. Semaglutide's cardiovascular benefits, including blood pressure reduction and improved blood sugar control, typically outweigh any generic weight-loss-related risk in healthy individuals.

How does PlexusDx compounded semaglutide compare to brand Ozempic in terms of safety?

PlexusDx compounded semaglutide contains the same active ingredient as Ozempic and comes from licensed 503A compounding pharmacies meeting strict pharmaceutical standards. The main difference is cost—starting at $149/month—and personalized dosing based on your medical history rather than a one-size-fits-all approach.

What genetic factors influence my clot risk with GLP-1 therapy?

While PlexusDx's Precision Peptide Genetic Test identifies how your genes affect peptide metabolism and GLP-1 response, actual blood clotting risk requires evaluation for specific thrombophilia genes through separate medical testing.

Should I avoid semaglutide if I'm on blood thinners?

Taking anticoagulants does not automatically contraindicate semaglutide, but your PlexusDx provider and primary care physician must coordinate care to monitor your bleeding risk and medication interactions. Many patients safely combine anticoagulants with GLP-1 therapy under appropriate medical supervision.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves